News AstraZeneca PLC

Stocks

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:29 2026-10-02 EDT			5-day change	1st Jan Change
11,870.00 ^GBX	-1.35%		-5.43%	-13.92%

10-02	AbbVie joins US government pilot to test drug discount rebates	RE
10-02	Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion	DJ

All News

Mentions Relevance

10-02	AstraZeneca, Daiichi Sankyo to Evaluate Datroway Combo Across Tumor Types with Summit Therapeutics	MT
10-02	Daiichi, AstraZeneca enter clinical trial cooperation with Summit	AN
10-02	AstraZeneca, Daiichi Sankyo, Summit Therapeutics Partner Test Cancer Drug Combination	MT
10-02	AstraZeneca, Daiichi Sankyo, Summit Therapeutics to Collaborate on Cancer Combination Therapy Trials	MT
09-30	AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating	ZD
09-29	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Weigh Tech Rebound	MT
09-29	Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration	MT
09-29	AstraZeneca PLC : Jefferies keeps its Buy rating	ZD
09-29	Summit soars after $2 billion investment from AstraZeneca for cancer therapies	RE
09-29	AstraZeneca PLC : RBC reaffirms its Buy rating	ZD
09-29	AstraZeneca PLC : JP Morgan maintains a Buy rating	ZD
09-29	AstraZeneca invests $2bn in Summit Therapeutics
09-29	AstraZeneca PLC : Deutsche Bank is Neutral	ZD
09-29	Hutchmed says AstraZeneca files US application for Orpathys	AN
09-29	Astra files US cancer NDA; Close Bros loss narrows	AN
09-29	AstraZeneca, Hutchmed Seek US FDA Nod for Lung Cancer Combination Therapy	MT
09-28	AstraZeneca to Buy $2 Billion of New Equity in Summit Therapeutics	MT
09-28	AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination	RE
09-28	AstraZeneca files US FDA application for Hutchmed lung cancer drug combination	RE
09-28	Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion	MT
09-28	AstraZeneca to invest USD2 billion in Summit Therapeutics	AN
09-28	AstraZeneca Invests $2 Billion in Summit Therapeutics; Enters Clinical Collaboration	MT
09-28	AstraZeneca : announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer	PU
09-28	AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs	DJ
09-25	AstraZeneca?s IMFINZI Plus Neoadjuvant Enfortumab Vedotin Receives Priority Review In The US For Patients With Muscle-Invasive Bladder Cancer	CI